Skip to main content
SpringerLink
Log in

Effect of Nonadherence on Levetiracetam Pharmacokinetics and Remedial Dose Recommendations Using Monte Carlo Simulations

  • Original Research Article
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and Objective

Nonadherence to levetiracetam (LEV) use can result in subtherapeutic concentrations and increase the risk of the occurrence of seizures. The impact of missing LEV doses on its pharmacokinetics and evidence of the appropriate remedial dose is lacking. This study has determined the influence of missed LEV doses on its pharmacokinetics and has explored the appropriate remedial dosage regimens.

Methods

Monte Carlo simulation was used to assess the impacts of different remedial dosage regimens on LEV concentrations. Simulated LEV concentrations outside the individual therapeutic range were calculated for the compliance scenario and for each of the remedial dosage regimens. The percentage of deviation from the full compliance scenario was also calculated. The regimen with the lowest percentage of deviation was considered the most appropriate.

Results

The suitable LEV remedial dose varied across the delay times. For one missed dose, a remedial regimen with a regular dose followed by the usual dose was suitable for a delay time of less than 6 h, while a replacement with a regular dose followed by a partial dose appeared to be appropriate for a delay time of 6 h and longer. This was justified based on the concerns of LEV toxicity when the remedial dose is close to the next scheduled dose. For two consecutive missed doses, a remedial dose with one and a half of the regular dose was suitable if the gap between that and the next dose was greater than 6 h.

Conclusions

The appropriate remedial dosage regimen for one and two consecutive missed doses of LEV have been proposed. These remedial regimens, however, should be applied with clinicians’ judgment based on the clinical status of the patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. UCB Group of companies. KEPPRA (levetiracetam) tablets [package insert]. US Food and Drug Administration website. https://www.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s099,021505s038lbl.pdf. Accessed 15 Apr 2020.

  2. Methaneethorn J, Leelakanok N. Population pharmacokinetics of Levetiracetam: a systematic review. Curr Clin Pharmacol. 2021;60:305–18.

    Article  Google Scholar 

  3. Murphy JE. Clinical pharmacokinetics: ASHP; 2011.

  4. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707–24.

    Article  CAS  Google Scholar 

  5. Hernández-Mitre MP, Medellín-Garibay SE, Rodríguez-Leyva I, Rodríguez-Pinal CJ, Zarazúa S, Jung-Cook HH, et al. Population pharmacokinetics and dosing recommendations of levetiracetam in adult and elderly patients with epilepsy. J Pharm Sci. 2020;109:2070–8.

    Article  Google Scholar 

  6. Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.

    Article  Google Scholar 

  7. Agrawal A, Banergee A. A review on pharmacokinetics of levetiracetam in neonates. Curr Drug Metab. 2017;18(8):727–34.

    Article  CAS  Google Scholar 

  8. Depositario-Cabacar DT, Peters JM, Pong AW, Roth J, Rotenberg A, Riviello JJ Jr, et al. High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia. 2010;51(7):1319–22.

    Article  CAS  Google Scholar 

  9. May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25(6):690–9.

    Article  CAS  Google Scholar 

  10. Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet. 2007;46(6):503–12.

    Article  CAS  Google Scholar 

  11. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on therapeutic strategies. Epilepsia. 2008;49(7):1239–76.

    Article  CAS  Google Scholar 

  12. Leppik I, Rarick J, Walczak T, Tran T, White J, Gumnit R. Effective levetiracetam doses and serum concentrations: age effects. Epilepsia. 2002;43:240.

    Google Scholar 

  13. Getnet A, Woldeyohannes SM, Bekana L, Mekonen T, Fekadu W, Menberu M, et al. Antiepileptic drug nonadherence and its predictors among people with epilepsy. Behav Neurol. 2016;2016:3189108.

    Article  Google Scholar 

  14. Faught RE, Weiner JR, Guérin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia. 2009;50(3):501–9.

    Article  Google Scholar 

  15. Ogboi Sonny J, Babajide F, Ademola OA, Olabunmi O, Agu P U. Evaluation of factors influencing medication adherence in patients with epilepsy in rural communities of Kaduna State, Nigeria. Neurosci Med. 2011;2(4):299-305.

  16. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49(3):446–54.

    Article  Google Scholar 

  17. Samsonsen C, Reimers A, Bråthen G, Helde G, Brodtkorb E. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study. Epilepsia. 2014;55(11):e125–8.

    Article  Google Scholar 

  18. Gu J, Guo Y, Jiao Z, Ding J, Li G-F. How to handle delayed or missed doses: a population pharmacokinetics perspective. Eur J Drug Metab Pharmacokinet. 2020;45(2):163–72.

    Article  CAS  Google Scholar 

  19. Yu E-Q, Jiao Z, Wang C-Y, Ding J-J, Zhang X-H. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations. Epilepsy Behav. 2019;96:132–40.

    Article  Google Scholar 

  20. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997;6(2):87–93.

    Article  CAS  Google Scholar 

  21. Kuzmanova R, Stefanova I, Stambolieva K. Significance of noncompliance when treating patients with epilepsy. Neurol Neurochir Pol. 2018;52(2):215–21.

    Article  Google Scholar 

  22. Ito S, Yano I, Hashi S, Tsuda M, Sugimoto M, Yonezawa A, et al. Population pharmacokinetics modeling of levetiracetam in pediatric and adult patients with epilepsy by using routinely monitored data. Ther Drug Monit. 2016;38(3):371–8.

    Article  CAS  Google Scholar 

  23. Karatza E, Markantonis SL, Savvidou A, Verentzioti A, Siatouni A, Alexoudi A, et al. Pharmacokinetics and Pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. Xenobiotica. 2020;50(9):1090–1100.

  24. Toublanc N, Lacroix BD, Yamamoto J. Development of an integrated population pharmacokinetics model for oral levetiracetam in populations of various ages and ethnicities. Drug Metab Pharmacokinet. 2014;29(1):61–8.

    Article  CAS  Google Scholar 

  25. Ding J, Zhang Y, Jiao Z, Wang Y. The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation. Acta Pharmacol Sin. 2012;33(11):1431–40.

    Article  CAS  Google Scholar 

  26. Wang C, Jiao Z, Ding J, Yu E, Zhu G. Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations. Epilepsy Behav. 2020;111:107265.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, 65000, Thailand

    Janthima Methaneethorn

  2. Center of Excellence for Environmental Health and Toxicology, Naresuan University, Phitsanulok, Thailand

    Janthima Methaneethorn

Authors
  1. Janthima Methaneethorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janthima Methaneethorn.

Ethics declarations

Funding

No funding was received to conduct the study.

Conflict of interest

None to declare.

Ethics approval

This study did not require ethics approval since it was based on simulations.

Consent to publish

Not applicable.

Code availability

Not applicable.

Availability of data and materials

Not applicable.

Consent to participate

Not applicable to this study as it was based on simulations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Methaneethorn, J. Effect of Nonadherence on Levetiracetam Pharmacokinetics and Remedial Dose Recommendations Using Monte Carlo Simulations. Eur J Drug Metab Pharmacokinet 47, 667–676 (2022). https://doi.org/10.1007/s13318-022-00774-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-022-00774-9

Search

Navigation